Archive: November, 2022

11

Nov2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
November 11, 2022

11

Nov2022

Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)

0  
November 11, 2022

11

Nov2022

Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety

0  
November 11, 2022